Actively Recruiting
Prospective Cohort Study in Patients With NAFLD
Led by University of Zurich · Updated on 2012-02-24
150
Participants Needed
1
Research Sites
1039 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
To assess the importance of intracellular signalling pathways and its deregulation in adiposity and diabetes-related insulin resistance, liver tissue samples of patients suffering from non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH)will be analyzed prospectively from a liver tissue bank.
CONDITIONS
Official Title
Prospective Cohort Study in Patients With NAFLD
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with histologically confirmed fatty liver disease
You will not qualify if you...
- History of significant alcohol consumption
- Viral hepatitis
- Autoimmune hepatitis
- Metabolic diseases (e.g. hemochromatosis, M. Wilson, alpha 1-antitrypsin deficiency)
- Hepatotoxic medication (e.g. amiodarone).
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University Hospital Zurich, Endocrinology and Diabetology
Zurich, Canton of Zurich, Switzerland, 8091
Actively Recruiting
Research Team
O
Oliver Tschopp
CONTACT
G
Giatgen Spinas, Professor, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here